AI Communis Pte. Ltd

We develop automatic speech recognition (ASR) SaaS solutions. Our ASR engines are developed by our Co-founder, Ian Lane, one of the best R&D teams at Carnegie Mellon University. Our recent product, Auris Edit, aims to make digital content accessible to the world.
Auris Edit enables content creators to easily create caption, transcription and inserting foreign subtitles, reducing their 50% of post-editing time. Creators can spend more time on contents creation rather than on less creative editing processes.
Our primary target is light users like mid-entry level YouTubers, or freelancers who help top YouTubers to add captions/subtitles. YouTube has over 50m content creators, and only with YouTube, we expect that the demand is high.
Captions/Subtitles are a must-have feature for content creators because 60% of YouTube views are from non-native English speakers, say people in South East Asia!
So Auris Edit will first target Asian market making digital content accessible.

Read More→

Acumen Research Labs

Acumen has developed AcuSeptTM — a novel, blood-based Sepsis Host Response test using sepsis-specific mRNA biomarkers — that can assist the doctos to detect sepsis in patients in 4-5 hrs, earlier and more accurately than current methods.

Intended Use:
AcuSeptTM generates diagnostic scores which fall in the range of either above or below a validated threshold level that determines the risk of sepsis. AcuSeptTM results are to be used in conjunction with clinical assessments and other laboratory findings as an aid to identify patients with low or high risk of infection and sepsis.

Clinical Utility:
・To differentiate patients with and without infection
・To differentiate patients with and without sepsis
・Can identify sepsis early

Read More→

Ampotech Pte Ltd

Ampotech develops internet of things (IoT) hardware and AI-enabled software to help businesses collect, analyze, and integrate electricity usage data from the built environment to deliver intelligent solutions and services. Launched in 2015 and headquartered in Singapore, Ampotech is supported by investors from the electronics, telecommunications, and deep tech sectors, with customers throughout the Asia Pacific region in industries such as energy & facility services, commercial real estate, manufacturing, and utilities.

Read More→

Advent Access Pte Ltd

Advent Access is a medical technology startup focused on end-stage renal disease management. A Stanford StartX company and spin-off from A*STAR, Advent’s mission is to pioneer innovations to significantly reduce dialysis cost and restore quality of life for kidney failure patients. The company’s first product is the av-Guardian™ – an award-winning implant technology that aims to improve vascular access reliability, enable less-painful self-cannulation and, in the long run, potentially reduce vascular access related hospitalizations. The av-Guardian™ forms a key component of Advent Access’ dialysis-machine agnostic platform to empower patients to perform hemodialysis independently, safely and more affordably – at home or in novel care environments.
For more information on Advent Access, please visit

Read More→

Craft Health Pte Ltd

At Craft Health, we are building a platform for 3D printed personalized healthcare. Possible applications include personalized nutrition, decentralized clinical trials, personalized medicine, and 3D printing for orphan drugs.

Since we launched in May 2019, we have:

Hardware: In-house developed 3D printer specialized for nutraceuticals and pharmaceuticals. Our 3D printer is designed for Good Manufacturing Practice (GMP) and the 3D printing process does not involve heat or ultraviolet (UV) curing, enabling a wide range of active ingredients to be used.
Software: 3D printing software
3D printable formulations: A series of proprietary 3D printable formulations for different controlled released profiles (Immediate/sustained/delayed release) that can be combined in a single 3D printed tablet.
Specialty products: Patent pending 3D printed capsule that converts once daily dosing to once weekly.

Read More→

BioCheetah Pte Ltd

BioCheetah Pte Ltd (Co. Reg. No. 201803287H) is a Singapore-based, A*STAR-IMCB spin-off diagnostics company. It is primarily set up to develop and commercialize non-invasive, protein-based diagnostic applications. First diagnostic applications in development are based on the proprietary bladder cancer biomarkers and detection antibodies discovered and developed in IMCB by BioCheetah’s Scientific Founder (Prof. Jean-Paul Thiery) and the co-Founder/Chief Executive Officer (Dr. Kian-Chung Lee). Both Intellectual Property of bladder cancer biomarkers and detection antibodies are licensed from A*STAR. Products to be developed include professional use in-vitro diagnostic ELISA and Point-of-care test (POCT) kits. The kits will employ a novel multiplex urine-based biomarkers panel with high sensitivity and specificity for diagnosis and monitoring of bladder cancer. BioCheetah’s target markets are to encompass local and overseas public and private healthcare providers. BioCheetah is in the midst of building an ISO 13485 production facility at Block 79, JTC LaunchPad in Singapore, setting up its Quality Management System (QMS) for the purpose of development and manufacturing of its diagnostic products as well as in discussion with SingHealth and overseas hospitals for clinical validation of the to-be-developed bladder cancer diagnostic products.

Read More→

Widuz Pte Ltd

Widuz is developing a new class of renewable and sustainable material called BVL™ (Bamboo Veneer Lumber), which is a high-performance patented structural lumber synthesized from bamboo fibres. BVL is up to 3 times stronger than timber while is not susceptible to any decay or degradation, and is much more dimensionally stable. BVL is suitable for construction of modular prefab buildings in place of other non-renewable construction materials such as concrete and steel.

Read More→

Ministry of Movement Pte Ltd (aka SWAT)

SWAT is a high-tech mobility company that focuses on demand responsive, high capacity ride-sharing technology. With a world-class routing engine that dynamically matches vehicle routes based on a passenger’s booking location, city governments are able to utilise the software to optimise public transport and improve traffic situations. SWAT has implementations in Singapore and Sydney, and will soon be across ASIAN cities. SWAT also uses its technology to improve corporate staff transport that brings higher convenience for staff and reduces costs through greater efficiencies.

Read More→